EA202192466A1 - Применение фоллистатина для прогнозирования риска диабета 2 типа - Google Patents

Применение фоллистатина для прогнозирования риска диабета 2 типа

Info

Publication number
EA202192466A1
EA202192466A1 EA202192466A EA202192466A EA202192466A1 EA 202192466 A1 EA202192466 A1 EA 202192466A1 EA 202192466 A EA202192466 A EA 202192466A EA 202192466 A EA202192466 A EA 202192466A EA 202192466 A1 EA202192466 A1 EA 202192466A1
Authority
EA
Eurasian Patent Office
Prior art keywords
follistatin
diabetes
prediction
type
risk
Prior art date
Application number
EA202192466A
Other languages
English (en)
Inventor
Янг Де Маринис
Original Assignee
Лундох Диагностикс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лундох Диагностикс Аб filed Critical Лундох Диагностикс Аб
Publication of EA202192466A1 publication Critical patent/EA202192466A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Library & Information Science (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)

Abstract

В изобретении подробно описано применение фоллистатина в качестве биомаркера для ранней диагностики и/или прогнозирования диабета 2 типа, причем секреция фоллистатина в печени регулируется GCKR, применение которого предусматривается в данном документе. Кроме того, в данном документе раскрыт способ составления профиля биомаркеров для раннего прогнозирования диабета 2 типа у человека.
EA202192466A 2019-03-28 2020-03-30 Применение фоллистатина для прогнозирования риска диабета 2 типа EA202192466A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950381 2019-03-28
PCT/EP2020/058971 WO2020193808A1 (en) 2019-03-28 2020-03-30 Use of follistatin in type 2 diabetes risk prediction

Publications (1)

Publication Number Publication Date
EA202192466A1 true EA202192466A1 (ru) 2022-02-16

Family

ID=70058386

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192466A EA202192466A1 (ru) 2019-03-28 2020-03-30 Применение фоллистатина для прогнозирования риска диабета 2 типа

Country Status (13)

Country Link
US (1) US20220252615A1 (ru)
EP (1) EP3948294B1 (ru)
JP (1) JP2022526227A (ru)
KR (1) KR20210144809A (ru)
CN (1) CN114026426B (ru)
AU (1) AU2020245775A1 (ru)
BR (1) BR112021019287A2 (ru)
CA (1) CA3134929A1 (ru)
EA (1) EA202192466A1 (ru)
ES (1) ES2954164T3 (ru)
MX (1) MX2021011807A (ru)
PL (1) PL3948294T3 (ru)
WO (1) WO2020193808A1 (ru)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
WO2006066263A1 (en) * 2004-12-17 2006-06-22 Entelos, Inc. Assessing insulin resistance using biomarkers
BRPI0617332A2 (pt) * 2005-10-11 2011-07-26 Tethys Bioscience Inc marcadores asoociados ao diabetes e mÉtodos de uso dos mesmos
CA2659082A1 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
JP2010502946A (ja) * 2006-09-01 2010-01-28 アメリカン タイプ カルチャー コレクション ２型糖尿病を診断および処置するための組成物および方法
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2010049179A1 (en) * 2008-10-31 2010-05-06 B.R.A.H.M.S. Ag Arginine vasopressin pro-hormone as predictive biomarker for diabetes
US20120157378A1 (en) * 2008-11-14 2012-06-21 Simin Liu Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes
CN105740641A (zh) * 2009-10-19 2016-07-06 提拉诺斯公司 集成的健康数据采集和分析系统
US9217747B2 (en) * 2009-10-29 2015-12-22 Health Diagnostic Laboratory, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
EP2943789A1 (en) * 2013-01-11 2015-11-18 Health Diagnostic Laboratory, Inc. Method of detection of occult pancreatic beta cell dysfunction in normoglycemic patients
RU2533836C1 (ru) * 2013-09-25 2014-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Воронежская государственная медицинская академия имени Н.Н. Бурденко Министерства здравоохранения Российской Федерации (ГБОУ ВПО ВГМА им. Н.Н. Бурденко Минздрава России) Способ мониторинга лиц с риском раннего развития атеросклероза и наличием сахарного диабета 2 типа
WO2015103553A1 (en) * 2014-01-06 2015-07-09 Liposcience, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
EP3143409A2 (en) * 2014-05-16 2017-03-22 Cézanne S.A.S. Early placenta insulin-like peptide (pro-epil)
EA201891085A1 (ru) * 2015-11-03 2018-11-30 Эпик Сайенсиз, Инк. Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания

Also Published As

Publication number Publication date
KR20210144809A (ko) 2021-11-30
EP3948294A1 (en) 2022-02-09
MX2021011807A (es) 2021-10-26
CN114026426A (zh) 2022-02-08
WO2020193808A1 (en) 2020-10-01
AU2020245775A1 (en) 2021-09-23
US20220252615A1 (en) 2022-08-11
CN114026426B (zh) 2024-10-25
EP3948294B1 (en) 2023-06-07
PL3948294T3 (pl) 2023-10-16
BR112021019287A2 (pt) 2022-02-01
EP3948294C0 (en) 2023-06-07
ES2954164T3 (es) 2023-11-20
CA3134929A1 (en) 2020-10-01
JP2022526227A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
MX2021009682A (es) Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos.
CL2020002225A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la enfermedad inflamatoria intestinal
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
BR112014013082A2 (pt) método para detectar adutos nucleossomos
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
MX2020010815A (es) Biomarcadores para enfermedad de injerto contra hospedero.
EA201792669A1 (ru) Igfbp3 и его применение
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
ATE507720T1 (de) Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2021002071A (es) Metodos relacionados con la gravedad y progresion de la lesion premaligna bronquial.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
NZ729773A (en) Biomarkers for disease progression in melanoma
EA202192130A1 (ru) Специфичные к ltbp-комплексу ингибиторы tgf и их применение
ES2679289T3 (es) Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa
FR3061305B1 (fr) Methode de diagnostic des qualites esthetiques de la peau
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
EA202192466A1 (ru) Применение фоллистатина для прогнозирования риска диабета 2 типа
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
MX2020004507A (es) Ensayos y métodos para determinar la expresión del gen de quimiotaxina 2 derivada de leucocitos (lect2).